Picard Medical, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 3, 2026 to Discuss Your Rights – PMI

Core Viewpoint - The Gross Law Firm is notifying shareholders of Picard Medical, Inc. (NYSE: PMI) about a class action lawsuit due to allegations of fraudulent activities affecting the company's stock price during a specified period [1][3]. Group 1: Allegations - The complaint alleges that during the class period from September 2, 2025, to October 31, 2025, Picard Medical was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [3]. - It is claimed that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [3]. - The public statements and risk disclosures made by Picard Medical allegedly omitted any mention of false rumors and artificial trading activity that were driving the stock price [3]. - As a result of these actions, the defendants' positive statements regarding the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [3]. Group 2: Class Action Details - Shareholders who purchased shares of PMI during the class period are encouraged to register for the class action, with a deadline set for April 3, 2026, to seek lead plaintiff status [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [4]. - Participation in the case does not incur any cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [5]. - The Gross Law Firm seeks recovery for investors who incurred losses due to misleading statements or omissions that led to artificial inflation of a company's stock [5].